UroGen Pharma Ltd. is on track to launch its first drug, a novel gel formulation of the chemotherapy drug mitomycin for low-grade upper tract urothelial cancer (LG UTUC), in the first half of 2020 and is ramping up its commercial plans for the launch, which could face some unique challenges.
The company's management – including chairman Arie Belldegrun, the former Kite Pharma Inc